Cambridge Cognition falls short with £6m IPO
This article was originally published in Clinica
UK neuropsychological test developer Cambridge Cognition has succeeded in going public but, like many of its peers carrying out IPOs recently, has only raised a fraction of its target amount. The company raised a total of £6.4 million ($9.8 million): £5 million from the placement of new ordinary shares; and £1.4 million through the sale of existing ordinary shares, all priced at 70p each. However, Cambridge Cognition had originally hoped to bring in up to £15 million from the IPO (www.clinica.co.uk, 26 March 2013). The company, which is now listed on the London Stock Exchange's AIM market under the ticker symbol COG, has a market cap of around £11.8 million.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.